Siren LLC’s NovoCure NVCR Stock Holding History

Siren LLC’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-350,884	Closed	-$5.48M	–	125
2024 Q3	$5.48M	Buy	+350,884	New	+$6.36M	0.27%	63

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Siren LLC's NVCR Position: Q4 2024 in Review

Siren LLC sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 350,884 shares — an estimated $5.48M sold.

Siren LLC first reported a position in NVCR in Q3 2024 and held it in 1 quarter. The position peaked at $5.48M in Q3 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

Siren LLC reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
Siren LLC sold 350,884 NovoCure shares in Q4 2024, an estimated $5.48M.
Siren LLC first reported a position in NovoCure in Q3 2024 and held it in 1 quarter.
Siren LLC's NovoCure position peaked at $5.48M in Q3 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.